Activities of Ryszard CZARNECKI related to 2021/2007(INI)
Shadow opinions (1)
OPINION on an intellectual property action plan to support the EU’s recovery and resilience
Amendments (4)
Amendment 8 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2 a. Welcomes the proposals for measures to promote the effective use and implementation of intellectual property, to facilitate access to and exchange of assets protected by intellectual property rights and to combat infringements of intellectual property rights; points out, however, that it is very important that these measures should not result in new or excessive obligations on businesses, in particular in the SME sector
Amendment 17 #
Draft opinion
Paragraph 3
Paragraph 3
3. Strongly encourages the Commission to assist producers and their associations as well as local authorities in developing countries in unlocking the potential of IP and reaping the economic value of local innovations, geographical indications and traditional knowledge; encourages, moreover, consultation with business representatives and their associations, as well as with other interested groups, in order to collect and analyse the available data and information, with a view to ensuring that decisions taken in this field take into account the interests of all stakeholders in the broadest and most favourable manner possible; reiterates its call, in this regard, to respect the progress achieved in the international protection of indigenous peoples’ rights over their genetic resources and associated traditional knowledge;
Amendment 23 #
Draft opinion
Paragraph 4
Paragraph 4
4. Recognises that IP systems contribute to the development of new medicines, but stresses that they must comply with international human rights law and public health requirements; notes that strong IPRs may limit access to medicines in developing countries while not necessarily encouraging pharmaceutical innovation that responds to the needs of developing countries; stresses at the same time that producers of generic medicines, unlike producers of innovative medicines, tend to be more regional; asks the Commission in particular to promote regulatory solutions that encourage competition in generic medicine production while maintaining a balance between generic and innovative medicines;
Amendment 28 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. welcomes the announcement of the revision and harmonisation of the legislation on industrial designs and the recognition of the need to develop the protection of geographical indications for non-agricultural products; recognises that such measures are necessary and can have a very positive impact on business competitiveness;